Adrenocortical carcinoma: The management of metastatic disease

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 2, 2014, Pages 123-132

  Fay, André P ^a   Elfiky, Aymen ^a,b,c   Teló, Gabriela H ^d   McKay, Rana R ^a   Kaymakcalan, Marina ^a   Nguyen, Paul L ^a,b,c   Vaidya, Anand ^b,c   Ruan, Daniel T ^a,b,c   Bellmunt, Joaquim ^a,b,c   Choueiri, Toni K ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOSLIN DIABETES CENTER   (United States)

Author keywords

Adrenocortical carcinoma; Metastatic disease; Targeted therapies; Therapeutics

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; BETA CATENIN; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FIGITUMUMAB; FLUOROURACIL; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOTANE; POLO LIKE KINASE 1; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; WNT PROTEIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CORTEX CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR ABLATION; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMAL; DISEASE MANAGEMENT; PATHOLOGY; SECONDARY;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MANAGEMENT; HUMANS;

EID: 84908311835     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.009     Document Type: Review

References (97)

1. Third national cancer survey: incidence data. National Cancer Institute Monograph 1975, 41(March):i-x. 1-454.
2. Kebebew E., Reiff E., Duh Q.Y., Clark O.H., McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg 2006, 30(May (5)):872-878.
3. Koschker A.C., Fassnacht M., Hahner S., Weismann D., Allolio B. Adrenocortical carcinoma - improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes 2006, 114(February (2)):45-51.
4. Pianovski M.A., Maluf E.M., de Carvalho D.S., et al. Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer 2006, 47(July (1)):56-60.
5. Figueiredo B.C., Sandrini R., Zambetti G.P., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 2006, 43(January (1)):91-96.
6. Sirianni R., Zolea F., Chimento A., et al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. J Clin Endocrinol Metab 2012, 97(December (12)):E2238-E2250.
7. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322(April (17)):1195-1201.
8. Barlaskar F.M., Spalding A.C., Heaton J.H., et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009, 94(January (1)):204-212.
9. Raymond V.M., Everett J.N., Furtado L.V., et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 2013, 31(August (24)):3012-3018.
10. Libe R., Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005, 153(October (4)):477-487.
11. Koch C.A., Pacak K., Chrousos G.P. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002, 87(December (12)):5367-5384.
12. Lerario A.M., Moraitis A., Hammer G.D. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 2014, 386(April (1-2)):67-84. [Epub 2013 Nov 9]. 10.1016/j.mce.2013.10.028.
13. Ayala-Ramirez M., Jasim S., Feng L., et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 2013, 169(October (6)):891-899. [Print 2013 Dec]. 10.1530/EJE-13-0519.
14. Dackiw A.P., Lee J.E., Gagel R.F., Evans D.B. Adrenal cortical carcinoma. World J Surg 2001, 25(July (7)):914-926.
15. Zini L., Porpiglia F., Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011, 60(November (5)):1055-1065.
16. Fassnacht M., Libe R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011, 7(June (6)):323-335.
17. Bellantone R., Ferrante A., Boscherini M., et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997, 122(December (6)):1212-1218.
18. Schulick R.D., Brennan M.F. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999, 6(December (8)):719-726.
19. Datrice N.M., Langan R.C., Ripley R.T., et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012, 105(June (7)):709-713.
20. Pommier R.F., Brennan M.F. An eleven-year experience with adrenocortical carcinoma. Surgery 1992, 112(December (6)):963-970. [discussion 970-961].
21. Erdogan I., Deutschbein T., Jurowich C., et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 2013, 98(January (1)):181-191.
22. Gaujoux S., Al-Ahmadie H., Allen P.J., et al. Resection of adrenocortical carcinoma liver metastasis: is it justified?. Ann Surg Oncol 2012, 19(August (8)):2643-2651.
23. Habra M.A., Ejaz S., Feng L., et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013, 98(January (1)):192-197.
24. Hermsen I.G., Groenen Y.E., Dercksen M.W., Theuws J., Haak H.R. Response to radiation therapy in adrenocortical carcinoma. J Endocrinol Invest 2010, 33(November (10)):712-714.
25. Sabolch A., Feng M., Griffith K., Hammer G., Doherty G., Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011, 80(August (5)):1477-1484.
26. Reibetanz J., Kroiss M., Deutschbein T., et al. German adrenocortical carcinoma registry, Surgical therapy results and follow-up treatment. Chirurg 2012, 83(June (6)):528-535.
27. Percarpio B., Knowlton A.H. Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 1976, 15(August (4)):288-292.
28. Markoe A.M., Serber W., Micaily B., Brady L.W. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 1991, 14(April (2)):170-174.
29. King D.R., Lack E.E. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 1979, 44(July (1)):239-244.
30. Henley D.J., van Heerden J.A., Grant C.S., Carney J.A., Carpenter P.C. Adrenal cortical carcinoma - a continuing challenge. Surgery 1983, 94(December (6)):926-931.
31. Polat B., Fassnacht M., Pfreundner L., et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009, 115(July (13)):2816-2823.
32. Cerquetti L., Bucci B., Marchese R., et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer 2008, 15(June (2)):623-634.
33. Wood B.J., Abraham J., Hvizda J.L., Alexander H.R., Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003, 97(February (3)):554-560.
34. Mayo-Smith W.W., Dupuy D.E. Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results. Radiology 2004, 231(April (1)):225-230.
35. Soga H., Takenaka A., Ooba T., et al. A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. Urol Int 2009, 82(2):222-226.
36. Cazejust J., De Baere T., Auperin A., et al. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 2010, 21(October (10)):1527-1532.
37. Abraham J., Bakke S., Rutt A., et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002, 94(May (9)):2333-2343.
38. Fareau G.G., Lopez A., Stava C., Vassilopoulou-Sellin R. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 2008, 19(July (6)):637-644.
39. Haak H.R., Hermans J., van de Velde C.J., et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994, 69(May (5)):947-951.
40. Barzon L., Fallo F., Sonino N., Daniele O., Boscaro M. Comment - is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?. J Clin Endocrinol Metab 1999, 84(April (4)):1488-1489.
41. Vassilopoulou-Sellin R., Guinee V.F., Klein M.J., et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993, 71(May (10)):3119-3123.
42. Bergenstal D.M.H.R., Lipsett M.B., et al. Chemotherapy of adrenocortical cancer with o,p' DDD. Ann Intern Med 1960, 53:672-682.
43. Kasperlik-Zaluska A.A. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000, 33(October (10)):1191-1196.
44. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001, 25(July (7)):891-897.
45. Heilmann P., Wagner P., Nawroth P.P., Ziegler R. Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels. Med Klin 2001, 96(July (7)):371-377.
46. Terzolo M., Angeli A., Fassnacht M., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007, 356(June (23)):2372-2380.
47. Hermsen I.G., Fassnacht M., Terzolo M., et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENSATT multicenter study. J Clin Endocrinol Metab 2011, 96(June (6)):1844-1851.
48. Seki M., Nomura K., Hirohara D., et al. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 1999, 6(December (4)):529-533.
49. Baudin E., Docao C., Gicquel C., et al. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 2002, 13(November (11)):1806-1809.
50. van Slooten H., Moolenaar A.J., van Seters A.P., Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984, 20(January (1)):47-53.
51. Berruti A., Baudin E., Gelderblom H., et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(October (Suppl. 7)):vii. 131-8.
52. Mauclere-Denost S., Leboulleux S., Borget I., et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012, 166(February (2)):261-268.
53. Schteingart D.E. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 2007, 356(June (23)):2415-2418.
54. Chortis V., Taylor A.E., Schneider P., et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013, 98(January (1)):161-171.
55. Hoffman D.L., Mattox V.R. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin N Am 1972, 56(July (4)):999-1012.
56. Daffara F., De Francia S., Reimondo G., et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008, 15(December (4)):1043-1053.
57. Ahlman H., Khorram-Manesh A., Jansson S., et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001, 25(July (7)):927-933.
58. Sperone P., Ferrero A., Daffara F., et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010, 17(June (2)):445-453.
59. Williamson S.K., Lew D., Miller G.J., Balcerzak S.P., Baker L.H., Crawford E.D. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000, 88(March (5)):1159-1165.
60. Berruti A., Terzolo M., Pia A., Angeli A., Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998, 83(November (10)):2194-2200.
61. Khan T.S., Imam H., Juhlin C., et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000, 11(October (10)):1281-1287.
62. Fassnacht M., Terzolo M., Allolio B., et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012, 366(June (23)):2189-2197.
63. Urup T., Pawlak W.Z., Petersen P.M., Pappot H., Rorth M., Daugaard G. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. Br J Cancer 2013, 108(May (10)):1994-1997.
64. Berruti A., Sperone P., Bellini E., et al. Metronomic therapy concepts in the management of adrenocortical carcinoma. Horm Cancer 2011, 2(December (6)):378-384.
65. Germano A., Rapa I., Volante M., et al. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Mol Cell Endocrinol 2014, 382(January (1)):1-7. [Epub 2013 Sep 7]. 10.1016/j.mce.2013.08.023.
66. Choueiri T.K. Renal cell carcinoma. Hematol Oncol Clin N Am 2011, 25(August (4)):xiii-xiv.
67. Courtney K.D., Choueiri T.K. Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol 2010, 2(May (3)):209-219.
68. Patyna S., Arrigoni C., Terron A., et al. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 2008, 36(December (7)):905-916.
69. Lodish M.B., Stratakis C.A. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer 2010, 17(September (3)):R233-R244.
70. Kroiss M., Reuss M., Kuhner D., et al. Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Front Endocrinol 2011, 2:27.
71. Kroiss M., Quinkler M., Johanssen S., et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012, 97(October (10)):3495-3503.
72. Berruti A., Sperone P., Ferrero A., et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012, 166(March (3)):451-458.
73. Wortmann S., Quinkler M., Ritter C., et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010, 162(February (2)):349-356.
74. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(May (15)):1960-1966.
75. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.
76. Fassnacht M., Hahner S., Adam P., et al. Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma: results of pre-clinical studies. Annual meeting proceedings (post-meeting edition), 25 2007, [Abstr. 21025].
77. Quinkler M., Hahner S., Wortmann S., et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008, 93(June (6)):2057-2062.
78. Samnotra V., Vassilopoulou-Sellin R., Fojo A.T., et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Annual meeting proceedings (post-meeting edition), 25 2007, [Abstr. 15527].
79. Edgren M., Eriksson B., Wilander E., Westlin J.E., Nilsson S., Oberg K. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997, 17(March-April (2B)):1303-1309.
80. Gombos A., Metzger-Filho O., Dal Lago L., Awada-Hussein A. Clinical development of insulin-like growth factor receptor - 1 (IGF-1R) inhibitors: at the crossroad?. Invest New Drugs 2012, 30(December (6)):2433-2442.
81. Kirschner L.S. The next generation of therapies for adrenocortical cancers. Trends Endocrinol Metab 2012, 23(July (7)):343-350.
82. Haluska P., Worden F., Olmos D., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010, 65(March (4)):765-773.
83. Weigel B., Malempati S., Reid J.M., et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2014, 61(March (3)):452-456. [Epub 2013 Aug 17]. 10.1002/pbc.24605.
84. Carden C.P., Kim E.S., Jones R.L., et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 2530].
85. Sivendran S., Agarwal N., Gartrell B., et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev 2014, 40(February (1)):190-196. [Epub 2013 May 16]. 10.1016/j.ctrv.2013.04.005.
86. Doghman M., Lalli E. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol Cell Endocrinol 2012, 364(November (1-2)):101-104.
87. De Martino M.C., van Koetsveld P.M., Feelders R.A., et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer 2012, 19(Jun (3)):351-364.
88. Naing A., Kurzrock R., Burger A., et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011, 17(September (18)):6052-6060.
89. Fraenkel M., Gueorguiev M., Barak D., Salmon A., Grossman A.B., Gross D.J. Everolimus therapy for progressive adrenocortical cancer. Endocrine 2013, 44(August (1)):187-192.
90. Kim A.C., Reuter A.L., Zubair M., et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008, 135(August (15)):2593-2602.
91. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Science 2003, 94(March (3)):225-229.
92. Takahashi-Yanaga F., Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007, 104(August (4)):293-302.
93. Doghman M., Cazareth J., Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 2008, 93(August (8)):3222-3225.
94. Gross D.J., Munter G., Bitan M., et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006, 13(June (2)):535-540.
95. García-Donas J., Hernando Polo S., Guix M., et al. Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03. J Clin Oncol 2013, 31(Suppl.). [abstr 4587].
96. Northfelt D.W., Hamburg S.I., Borad M.J., et al. A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition. J Clin Oncol 2013, 31(15 Suppl.). [ASCO Annual Meeting Abstract].
97. Rini B.I., Garcia J.A., Cooney M.M., et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009, 15(October (19)):6277-6283.